Review: The spectrum of clinical features seen with alpha synuclein pathology

被引:58
|
作者
Barker, R. A. [1 ]
Williams-Gray, C. H. [1 ]
机构
[1] Univ Cambridge, Dept Clin Neurosci, John van Geest Ctr Brain Repair, Forvie Site, Cambridge CB2 0PY, England
基金
英国惠康基金;
关键词
alpha synucleinopathies; Parkinson's disease; SLEEP BEHAVIOR DISORDER; MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE DEMENTIA; GLUCOCEREBROSIDASE MUTATIONS; LEWY BODIES; NEURODEGENERATIVE DISEASE; NATURAL-HISTORY; INCREASES RISK; INCIDENT; DIAGNOSIS;
D O I
10.1111/nan.12303
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It has been recognized for many years that a number of chronic neurodegenerative diseases of the CNS are characterized by the development of intracellular inclusion bodies, but it is only relatively recently that the core proteins defining these pathologies have been defined. One such protein is alpha synuclein, that was found to be the main component of Lewy bodies in the late 1990s, and this discovery reinforced the emerging view that alpha synuclein was intimately linked to diseases characterized by this type of pathology - namely Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Furthermore at around this time, this same protein was also found within the glial inclusion bodies of patients dying with multiple system atrophy (MSA). These three disorders constitute the majority of patients with an alpha synucleinopathy', although there are a number of rarer conditions that can also cause this pathology including inherited metabolic disorders such as Gaucher's disease (GD). In this review, we will concentrate on PD, the commonest alpha synucleinopathy, and its associated dementia (PDD), as well as discussing DLB and MSA and will highlight how the clinical features of these conditions vary as a function of pathology.
引用
收藏
页码:6 / 19
页数:14
相关论文
共 50 条
  • [21] Enhanced alpha-synuclein pathology and exacerbated motor dysfunction in alpha-synuclein transgenic mice with autophagy deficiency
    Noda, Sachiko
    Sato, Shigeto
    Yamakado, Hodaka
    Takahashi, Ryosuke
    Hattori, Nobutaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 758
  • [22] Pathology and physiology of alpha-synuclein relevant to neurodegenerative diseases
    Kenji, UEDA
    JOURNAL OF NEUROCHEMISTRY, 2004, 88 : 6 - 6
  • [23] Tau and alpha-synuclein brainstem pathology in Alzheimer disease
    Attems, J
    Jellinger, KA
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2006, 32 (02) : 222 - 223
  • [24] Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
    Bras, Ines C.
    Outeiro, Tiago F.
    CELLS, 2021, 10 (02) : 1 - 19
  • [25] Is alpha-synuclein pathology a target for treatment of neurodegenerafive disorders?
    Windisch, M.
    Wolf, H. J.
    Hutter-Paier, B.
    Hofmeister, A.
    Wronski, R.
    CURRENT ALZHEIMER RESEARCH, 2007, 4 (04) : 446 - 457
  • [26] Alpha-synuclein pathology in the olfactory pathways of dementia patients
    Hubbard, Paul S.
    Esir, Margaret M.
    Reading, Margaret
    McShane, Rupert
    Nagy, Zsuzsanna
    JOURNAL OF ANATOMY, 2007, 211 (01) : 117 - 124
  • [27] Spinal Cord Pathology in Alpha-Synuclein Transgenic Mice
    Mendritzki, Sonja
    Schmidt, Saskia
    Sczepan, Teresa
    Zhu, Xin-Ran
    Segelcke, Daniel
    Luebbert, Hermann
    PARKINSONS DISEASE, 2010, 2010
  • [28] Tau and alpha-synuclein brainstem pathology in Alzheimer disease
    Jellinger, KA
    Attems, J
    ACTA NEUROPATHOLOGICA, 2005, 110 (03) : 330 - 330
  • [29] Alpha-synuclein pathology in neurodegeneration and aging human brain
    Jellinger, KA
    ACTA NEUROPATHOLOGICA, 2004, 108 (04) : 370 - 371
  • [30] Pulmonary sarcoidosis: from clinical features to pathology-narrative review
    Li, Yun
    Liang, Zhixin
    Zheng, Yiqiong
    Qiao, Juan
    Wang, Ping
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (03) : 3438 - 3444